These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37626090)

  • 1. Who wins the combat, CAR or TCR?
    Yun K; Siegler EL; Kenderian SS
    Leukemia; 2023 Oct; 37(10):1953-1962. PubMed ID: 37626090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR".
    Teppert K; Wang X; Anders K; Evaristo C; Lock D; Künkele A
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.
    Wu L; Wei Q; Brzostek J; Gascoigne NRJ
    Cell Mol Immunol; 2020 Jun; 17(6):600-612. PubMed ID: 32451454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure.
    Wachsmann TLA; Wouters AK; Remst DFG; Hagedoorn RS; Meeuwsen MH; van Diest E; Leusen J; Kuball J; Falkenburg JHF; Heemskerk MHM
    Oncoimmunology; 2022; 11(1):2033528. PubMed ID: 35127255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.
    Shafer P; Kelly LM; Hoyos V
    Front Immunol; 2022; 13():835762. PubMed ID: 35309357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.
    Akatsuka Y
    Front Immunol; 2020; 11():257. PubMed ID: 32184779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
    Chandran SS; Klebanoff CA
    Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exhaustion of CAR T cells: potential causes and solutions.
    Kouro T; Himuro H; Sasada T
    J Transl Med; 2022 May; 20(1):239. PubMed ID: 35606821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs.
    Anikeeva N; Panteleev S; Mazzanti NW; Terai M; Sato T; Sykulev Y
    J Biol Chem; 2021 Sep; 297(3):101033. PubMed ID: 34371020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies.
    Marhelava K; Krawczyk M; Firczuk M; Fidyt K
    Cells; 2022 May; 11(11):. PubMed ID: 35681499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A TCR-based Chimeric Antigen Receptor.
    Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
    Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redirection of CAR-T Cell Cytotoxicity Using Metabolic Glycan Labeling with Unnatural Sugars.
    Cha JH; Kim E; Lee HJ; Lee YH; Lee J; Kim E; Kim CH
    J Med Chem; 2023 Jun; 66(12):7804-7812. PubMed ID: 37261887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss.
    Furqan F; Shah NN
    Annu Rev Med; 2023 Jan; 74():279-291. PubMed ID: 36332638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions.
    Mishra A; Maiti R; Mohan P; Gupta P
    Eur J Haematol; 2024 Feb; 112(2):211-222. PubMed ID: 37705357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TCR and CAR Engineering of Primary Human T Cells.
    Edes I; Clauss J; Stahn R; Japp AS; Lorenz FKM
    Methods Mol Biol; 2022; 2521():85-93. PubMed ID: 35732994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function.
    Salter AI; Rajan A; Kennedy JJ; Ivey RG; Shelby SA; Leung I; Templeton ML; Muhunthan V; Voillet V; Sommermeyer D; Whiteaker JR; Gottardo R; Veatch SL; Paulovich AG; Riddell SR
    Sci Signal; 2021 Aug; 14(697):. PubMed ID: 34429382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs).
    Cassioli C; Patrussi L; Valitutti S; Baldari CT
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
    Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
    Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.